Kylin Sees Potential for pRNA with Aptamers, But Keeps Its Eye on RNA Interference | GenomeWeb

By Doug Macron

Seeing potential for its so-called packaging RNA technology with other therapeutic RNA molecules, Kylin Therapeutics is exploring the use of the technology in conjunction with aptamers, a company official told RNAi News this week.

Still, the company's main focus remains developing pRNA for RNAi, and the work with aptamers is being conducted primarily by academic collaborators, Kylin President and CEO Eric Davis said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.